[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,192,792
  • Shares Outstanding, K 102,955
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,843 M
  • EBITDA $ 4,387 M
  • 60-Month Beta 0.21
  • Price/Sales 5.63
  • Price/Cash Flow 18.69
  • Price/Book 2.55

Options Overview Details

View History
  • Implied Volatility 27.86% (+0.06%)
  • Historical Volatility 32.74%
  • IV Percentile 2%
  • IV Rank 7.22%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 2) 15.39 (1.93%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 1,163
  • Volume Avg (30-Day) 1,737
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 41,109
  • Open Int (30-Day) 39,518
  • Expected Range 781.62 to 812.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $12.89
  • Number of Estimates 6
  • High Estimate $15.06
  • Low Estimate $9.58
  • Prior Year $9.63
  • Growth Rate Est. (year over year) +33.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
637.80 +24.96%
on 07/23/26
813.63 -2.04%
on 08/11/26
+132.48 (+19.94%)
since 07/10/26
3-Month
591.52 +34.74%
on 06/02/26
813.63 -2.04%
on 08/11/26
+84.23 (+11.82%)
since 05/11/26
52-Week
541.00 +47.32%
on 10/13/25
821.11 -2.94%
on 01/09/26
+251.06 (+45.99%)
since 08/11/25

Most Recent Stories

More News
REGN DEADLINE: The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline

NEW YORK , Aug. 11, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

REGN : 797.00 (-1.37%)
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO , Aug. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in  Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit...

REGN : 797.00 (-1.37%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  ...

REGN : 797.00 (-1.37%)
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit

SAN FRANCISCO , Aug. 6, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 797.00 (-1.37%)
SueWallSt Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN

Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses...

REGN : 797.00 (-1.37%)
The Top 5 Analyst Questions From Regeneron’s Q2 Earnings Call

The Top 5 Analyst Questions From Regeneron’s Q2 Earnings Call

REGN : 797.00 (-1.37%)
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky

Ryan Crowe Regeneron securities defendant liability allegations focus on investor-facing statements about the Phase III Fianlimab-Libtayo Study before REGN shares declined $102.09 per share from the Class...

REGN : 797.00 (-1.37%)
REGN Stock Drop: If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Leading the Class Action Lawsuit

Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities...

REGN : 797.00 (-1.37%)
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit

SAN FRANCISCO , Aug. 4, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 797.00 (-1.37%)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

NEW YORK , Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

REGN : 797.00 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 80%. The market has dropped from extreme overbought territory, indicating a possible trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 825.17
2nd Resistance Point 819.40
1st Resistance Point 808.20
Last Price 797.00
1st Support Level 791.23
2nd Support Level 785.46
3rd Support Level 774.26

See More

52-Week High 821.11
Last Price 797.00
Fibonacci 61.8% 714.11
Fibonacci 50% 681.05
Fibonacci 38.2% 648.00
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.